Serum neuron-specific enolase and S-100 protein levels in children with some forms of symptomatic epilepsy as reflection of disregulative pathology of central nervous system
- Authors: Pugolovkin K.A1, Dombrovskaya E.A1
-
Affiliations:
- Russian Rehabilitation Center “Childhood”
- Issue: Vol 19, No 2-3 (2017)
- Pages: 23-27
- Section: Articles
- URL: https://ogarev-online.ru/2075-1753/article/view/94687
- ID: 94687
Cite item
Full Text
Abstract
Forming of pathological epileptic brain system accompanied by specific failure of cellular architechtonic, damages of membrane's excitability and cascade of neurochemical changes. Neuron-specific proteins perform a lot of integrative functions at the same time. Also they are the markers of structural damage. The aim of this investigation was searching of laboratory parameters which reproduce the grade of activity of pathologic process in central nervous system on different stages of epileptic syndrome. Materials and methods. There were examined 18 children 8 months to 11 years old. There were analyzed 44 species of serum for concentrations of NSE and S100 protein. Laboratory tests were made on stage of active course of epileptic syndrome, then on the stage of reduction of seizures and partial remission, and on stage of persistent remission. The investigation includes young patients with different types of symptomatic epilepsy. The ethiologic factors of epilepsy were perinatal hypoxia and ischemia, inborn malformations of brain, genetic syndroms. The patients were classified in 3 groups depending on stages of epileptic syndrome. Concentrations of serum NSE and S100 protein were analyzed in these groups. Conclusions. The results of measurements and its correlations were compared in each group of patients. The importance of complex assessment of NSE and S100 for children with epilepsy was identified. Laboratory data enable to characterize the stages of epileptic syndrome from the point of activity of pathologic process caused by disfunction of haemato-encephalic barrier among children with symptomatic epilepsy. Accounting the activity of pathologic (disregulative) process the improvement of therapeutic strategy becomes possible.
Full Text
##article.viewOnOriginalSite##About the authors
K. A Pugolovkin
Russian Rehabilitation Center “Childhood”
Email: pkirill-msk@mail.ru
врач-невролог, зав. психоневрологическим отд-нием 142031, Russian Federation, Moscow region, pos. sanatoriia “Gorki Leninskie”
E. A Dombrovskaya
Russian Rehabilitation Center “Childhood”рач-невролог психоневрологического отд-ния 142031, Russian Federation, Moscow region, pos. sanatoriia “Gorki Leninskie”
References
- Карлов В.А. Судорожный эпилептический статус. М.: МЕДпрессинфо, 2003.
- Карлов В.А. Эпилепсия. М.: Медицина, 1990.
- Commission of ILAE, 1989 Commission on Classification and Terminology of the International League Against Epilepsy, Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99.
- Дизрегуляционная патология нервной системы. Под ред. Е.И.Гусева, Г.Н.Крыжановского. М.: МИА, 2009.
- Мотавкин П.А., Черток В.М. Гистофизиология сосудистых механизмов мозгового кровообращения. М.: Медицина, 1980
- Крыжановский Г.Н. Дизрегуляционная патология. Патогенез. 2004; 2 (1).
- Guekht A, Gusev E, Shpak A. et al. Evoked potentials and brain plasticity in patients with localization-related epilepsy. Epilepsia 2001; 42 (Suppl. 2).
- LaRoshe S.M, Helmers S.L. Epilepsy in the elderly. Neurologist 2003; 9 (5).
- Dong W.K, Greenough W.T. Plasticity of nonneuronal brain tissue: roles in developmental disorders. Ment Retard Dev Disabil Res Rev 2004; 10 (2).
- Штарк М.Б. Мозгоспецифические антитела и функции нейронов. М.: Медицина, 1985
- Полетаев А.Б. Мозгоспецифические белки группы S-100, их эндогенные акцепторы и лиганды и регуляция метаболических процессов в нервной ткани. Автореф. дис. … д-ра мед. наук. М., 1988
- Зиньковский К.А., Яковлев Н.А., Морозов С.Г. Особенности клинико-иммунологических отношений при эпилепсии. Нейроиммунология. 2005; 3 (2
- Громов С.А., Липатова Л.В. Диагностика клинико-нейроиммунологических нарушений у больных эпилепсией с синдромом энцефалопатии, их иммунокоррекция и лечение. Методические рекомендации. СПб.: НИИПНИ им. В.М.Бехтерева, 2010.
- Gurnett C.A, Landt M, Wong M. Analysis of cerebrospinal fluid glial fibrillary acidic protein after seizures in children. Epilepsia 2003; 44 (11).
- Giardi E, Ramos A.J, Vanore G, Brusco A. Astrocytic response in hippocampus and cerebral cortex in an experimental epilepsy model. Neurochem Res 2004; 29 (2).
- Карякина Г.М., Надеждина М.В., Хинко М.А. Нейронспецифическая енолаза как индикатор поражения мозговой ткани при ишемическом инсульте. Неврологический вестн. 2007; 39 (Вып. 1).
- Рахимбаева Г.С., Рашидова Н.С. Нейронспецифическая енолаза в сыворотке крови как диагностический маркер эпилепсии. Междунар. неврологический журн. 2011; 2 (40).
- Галиева Г.Ю., Попонникова Т.В., Вавин Г.В. Нейронспецифическая енолаза и белок NS-100 как возможные маркеры поражения нервной системы при острых клещевых нейроинфекциях у детей. Сиб. мед. журн. 2008; 7.
- Palmio J, Peltola J, Vuorinen P. et al. Normal CSF neuron-specific enolase and S-100 protein levels in pacients with recent non-complicated tonic-clonic seizures. J Neurol Sci 2001; 183 (1).
- Leutmezer F, Wagner O, Baumgartner C. Serum S-100 pritein is not a suitable seizure market in temporal lobe epilepsy. J Epilepsia 2002; 43 (10): 1172-4.
- Palmio J, Keranen T, Alapirtti T. et al. Elevated serum neuron-specific enolase in patients with temporal lobe epilepsy: a video-EEG study. J Epilepsia 2008; 81 (2-3): 155-60.
- Tumani H, Otto M, Gefeller O. et al. Kinetics of serum neuron-specific enolase and prolactin in patients after single epileptic seizures. J Epilepsia 1999; 40 (6): 713-8.
Supplementary files
